'Back to Medicine' at Longevity Docs Cannes: A Peptide Traceability Checklist
Longevity Docs promotes evidence, supervision, and traceable peptide supply. FDA records show why patients and clinics must verify the ingredient, compounder, lot, and regulatory pathway.
Review note, August 28, 2026: This article now separates the event organizer’s position from FDA records. Unsupported enforcement history, attendance estimates, clinic migration claims, and certification claims were removed.
The March 2026 Longevity Docs newsletter presents its Cannes theme as “Back to Medicine”: evidence-based protocols, physician supervision, traceable supply chains, and accountability.
Founder David Luu uses the reported shutdown of Peptide Sciences as an example of a grey-market model becoming unstable. That is the organizer’s account and framing. The newsletter is also promoting its conference and Certified Longevity Doctor program, so it should not be treated as an independent regulatory finding.
The useful part of the message is the traceability test. Official FDA material shows why it matters.
What FDA status can and cannot tell you
The FDA compounding Q&A states that compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before they are marketed.
Sections 503A and 503B describe different compounding conditions:
- 503A generally concerns patient-specific compounding by licensed pharmacists or physicians under the statutory conditions.
- 503B permits a facility to register as an outsourcing facility and subjects it to additional federal requirements, including current good manufacturing practice and FDA inspection.
Neither label proves that a peptide is effective for longevity. Registration as a 503B outsourcing facility is not approval of every product it compounds.
Why the active ingredient matters
FDA maintains information about bulk drug substances used under section 503A and a separate page describing safety risks associated with nominated substances.
The safety-risk page includes substances promoted in longevity or recovery settings, such as BPC-157, CJC-1295, MOTS-c, and a thymosin beta-4 fragment. FDA describes concerns that can include limited human safety information, immunogenicity, impurity or active-ingredient characterization, and serious adverse-event reports for particular substances.
The exact category and FDA assessment can change. Check the current entry for the named ingredient rather than relying on “peptide therapy” as a category.
A traceability record for every compounded peptide
Before prescribing, dispensing, or receiving a compounded peptide, obtain a record that answers these questions:
| Field | Minimum information |
|---|---|
| Clinical purpose | Diagnosis or symptom, intended outcome, and why standard options are unsuitable |
| Active ingredient | Exact nonproprietary name, salt or form, concentration, dose, and route |
| Evidence | Human studies for the same ingredient, route, population, outcome, and duration |
| Regulatory pathway | Approved, off-label approved drug, compounded under 503A, supplied by a registered 503B facility, or investigational |
| Source | Manufacturer of the bulk substance, compounder, facility address, and responsible prescriber |
| Batch | Lot number, certificate of analysis, dates, storage conditions, and beyond-use date |
| Administration | Who prepares and administers it, aseptic controls where relevant, and concomitant medicines |
| Safety | Contraindications, adverse-event monitoring, stop criteria, emergency contact, and reporting route |
A certificate of analysis can help identify a batch, but it does not establish clinical efficacy or replace independent quality controls.
Questions for the clinic
- Why this exact peptide? Ask what diagnosed problem and patient-relevant outcome justify it.
- Why compounded? Ask why an approved product, standard treatment, or no treatment is not the better option.
- Who made this lot? Obtain the pharmacy or outsourcing facility and verify the record with the relevant regulator.
- What is known in humans? Animal mechanisms and influencer experience are not substitutes for clinical safety and efficacy data.
- What happens after treatment? Require a named clinician, monitoring interval, adverse-event route, and stop criteria.
For product-level regulatory distinctions, use the WLC peptide therapy guide.
What “Back to Medicine” would mean in practice
An event theme is not a quality standard. A certification is not evidence for a product. “Physician supervised” is not enough if the ingredient, source, indication, and monitoring remain opaque.
The phrase becomes useful only when a clinic can reproduce the chain from patient need to product identity, evidence, informed consent, batch, administration, and follow-up. If one link is missing, the buyer cannot independently verify what is being offered.
Main source: Longevity Docs newsletter, “Back to Medicine”, published March 8, 2026. Regulatory checks: FDA compounding Q&A and FDA safety risks for nominated bulk substances, reviewed August 28, 2026.